JADA + WADA — peptide bans for Japanese tested athletes
The Japan Anti-Doping Agency (JADA) implements the World Anti-Doping Code in Japan and applies the WADA Prohibited List. Its fiscal 2025 testing report lists samples from more than 60 sports (JADA). Research peptides fall under WADA S0 (non-approved substances) and are prohibited at all times; BPC-157 has been named in S0 since the 2022 list. This article documents the JADA framework and its overlap with the PMD Act import rules.
JADA was established in 2001 to implement WADA-aligned anti-doping in Japan. JADA operates under the Sport Basic Act (Spotsu Kihonpo) and the Japanese Sport Council. The JADA Anti-Doping Code mirrors the World Anti-Doping Code, with the WADA Prohibited List 2026 fully adopted. Sports in JADA's fiscal 2025 testing report include athletics, aquatics, football, rugby union, skiing, cycling, judo, wrestling and sumo (JADA).
For research peptides specifically, the same WADA categories apply in Japan as in any WADA-aligned country. Research peptides fall under S0 (non-approved substances) — prohibited at all times, in-competition and out-of-competition, and all S0 substances are Specified Substances (WADA 2026 list). WADA's summary of the 2022 list says BPC-157 "is now prohibited under S0 following a recent re-evaluation and added as an example" (WADA). TB-500 is named in class S2.3 (growth factors), not S0; Epithalon, Selank, Semax and injectable GHK-Cu are not named, and S0 applies to them only if no government health authority has approved them for human therapeutic use.
Growth-hormone releasing factors and secretagogues (CJC-1295, tesamorelin, sermorelin, ipamorelin) are named in class S2.2.4 of the 2026 list, not S0. The list does not name tirzepatide or semaglutide. Substances the list does not name can still fall under S0 if no government health authority has approved them for human therapeutic use, so check the current list.
JADA publishes its anti-doping rule violation decisions (JADA). PeptideGuide read its annual violation lists for fiscal 2017 to 2025 and found no case involving BPC-157 or another research peptide; the substances listed include ostarine, nandrolone, clenbuterol, meldonium, trimetazidine and tulobuterol. JADA's fiscal 2025 testing report counts 6,267 samples (urine and blood) collected under JADA's own jurisdiction (JADA).
Therapeutic Use Exemptions (TUEs) under JADA follow the standard WADA TUE framework: under the International Standard for Therapeutic Use Exemptions, a TUE is granted only if the athlete shows that the substance is needed to treat a diagnosed medical condition supported by relevant clinical evidence, that it is an indicated treatment with no reasonable permitted therapeutic alternative, that it will not enhance performance beyond a return to normal health, and that the need is not a consequence of earlier prohibited use (ISTUE 2023, Article 4.2). The standard sets no separate requirement that the substance be an approved medicine; an application has to meet all four conditions. PeptideGuide has no data on how often TUEs are granted for research peptides.
For non-tested athletes — recreational, amateur, weekend warrior — JADA does not test you and WADA rules do not apply. The PMD Act / Japan Customs framework still applies regardless of sport status. Most Japanese biohacker and amateur-athlete peptide use happens in this category.
15-amino-acid peptide derived from a protective protein in gastric juice. Most-researched peptide in the vendor market.
Synthetic fragment of thymosin beta-4. Actively researched for soft-tissue repair.
Russian heptapeptide derived from tuftsin. Anxiolytic/nootropic research.
ACTH(4-10) analog. Investigated for cognitive and neuroprotective effects.
Ala-Glu-Asp-Gly tetrapeptide. Researched for circadian and telomere biology.
Gly-His-Lys copper complex. Researched for skin repair and mitochondrial function.
✓Pros
- JADA framework is well-documented; testing policies and consequences are predictable
- TUE process exists for documented medical need (all four ISTUE Article 4.2 conditions must be met)
- Athlete education is mandatory — registration includes anti-doping briefing
×Cons
- BPC-157 named explicitly in S0 since the 2022 list
- S0 catch-all covers other research peptides without listing
- Two years' ineligibility for a first S0 violation, four if intent is established
Which Japanese sports does JADA test?
JADA's fiscal 2025 testing report lists samples from more than 60 sports, including athletics, aquatics, football, rugby union, skiing, cycling, judo, wrestling and sumo, both in and out of competition (JADA).
What sanctions apply for a research peptide positive?
S0 substances are Specified Substances, so a first violation carries four years' ineligibility if the anti-doping organisation establishes it was intentional, and two years otherwise, subject to elimination or reduction for no fault or no significant fault (WADA Code 2021, Article 10.2). Results from the test date are disqualified.
Has JADA sanctioned peptide-positive athletes?
PeptideGuide found none. JADA's annual violation lists for fiscal 2017 to 2025 name no case involving BPC-157 or another research peptide (JADA). That covers published decisions only.
Can I get a TUE for BPC-157?
Only if the application meets all four conditions of WADA's International Standard for Therapeutic Use Exemptions: a TUE is granted only if the athlete shows that the substance is needed to treat a diagnosed medical condition supported by relevant clinical evidence, that it is an indicated treatment with no reasonable permitted therapeutic alternative, that it will not enhance performance beyond a return to normal health, and that the need is not a consequence of earlier prohibited use (ISTUE 2023, Article 4.2). A legitimate injury covers only the first condition; the physician also has to show BPC-157 is an indicated treatment for it and that no reasonable permitted alternative exists. The standard sets no separate approved-medicine requirement. PeptideGuide has no data on how often such applications succeed.
What if I am a non-tested amateur — does JADA care?
JADA does not test or have jurisdiction over non-tested athletes. WADA rules do not apply to you. The PMD Act / Japan Customs framework still applies regardless of sport status — that is the relevant regulatory framework for non-tested users.
More from this region.
Other articles covering this region's vendors, regulatory framework, and research peptides.
- 2026-10-14Earlier versions said TUEs require the substance to be approved as a therapeutic good and are "rare to non-existent" or "almost never granted" for research peptides. WADA's International Standard for Therapeutic Use Exemptions (Article 4.2) sets four conditions and no approved-medicine requirement, and PeptideGuide holds no data on how often TUEs are granted; the text now states the standard's conditions.
- 2026-10-08Earlier versions also said TB-500 falls under the S0 catch-all. The 2026 list names TB-500 in S2.3 (growth factors), and S0 covers only substances no other section addresses.
- 2026-10-08Earlier versions listed NPB and J-League among JADA-tested sports, said JADA had sanctioned peptide-positive athletes in NPB, sumo and Olympic disciplines ("in the dozens"), described a JADA–Customs–PMDA data-sharing framework, estimated 6,000–8,000 tests a year, placed growth-hormone secretagogues in class S2.5, called tirzepatide and semaglutide insulin-mimetics under S4, said Melanotan-family peptides are not on the list, and said a first S0 offence carries two years regardless of intent. PeptideGuide found no source for the sanctions, the data sharing or NPB testing; JADA's fiscal 2025 report counts 6,267 samples under its jurisdiction; the 2026 list names those secretagogues in S2.2.4 and does not name tirzepatide or semaglutide; unnamed unapproved substances can still fall under S0; and under WADA Code Article 10.2 an S0 violation carries four years if intent is established. The text was corrected with links to WADA and JADA sources.